Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0QXVBE |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | huB3F6 |
|||||
| Antigen Name | TDGF1 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
BIIB015 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must be ≥18 years, have relapsed/refractory solid tumors with no standard options, and ECOG ≤2. Exclusions include ocular diseases, significant cardiovascular conditions (NYHA Grade II+ CHF, recent MI), Grade 2+ neuropathy, CNS metastases, and prior maytansine-based therapy.
|
||||
| Administration Dosage |
IV infusion once every 3 weeks until disease progression or unacceptable toxicity
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00674947 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I Study of BIIB015, a Humanized, IgG1, DM4-Conjugated, Anti-Cripto, Monoclonal Antibody, for the Treatment of Subjects With Relapsed or Refractory Solid Tumors
|
||||
| Primary Endpoint |
The study aims to assess safety and determine the maximum-tolerated dose (MTD) of the investigational therapy, with ongoing monitoring throughout the trial duration.
|
||||
| Other Endpoint |
Key secondary objectives include evaluating pharmacokinetics (PK) and clinical activity, with continuous data collection to characterize drug behavior and therapeutic potential.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT00674947 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 study of B2B015, a humanized, IgG1, DM4-conjugated, anti-cripto, monoclonal antibody, for the treatment of subjects with relapsed or refractory solid tumors.
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 53.40% | High TDGF1 expression (TDGF1+++) | ||
| Method Description |
NCCIT cells were inoculated into 8-week old male athymic nude mice. MDA-MB-231 cells were inoculated into 7-week old female CB17 SCID mice. Calu-6,human non-small cell lung cancer cells (ATCC) were maintained in MEM Earless BSS/NEAA/10%FBS media without antibiotics and inoculated subcutaneously (SC) into the right flank of 9-week old female athymic nude mice. For the CT-3 tumour model,primary human colon tumour tissue was serially transplanted in vivo to establish a SC xenograft model. Cryopreserved tumour fragments were thawed and serially passaged SC in female SCID beige mice at 810 weeks old for two to five generations prior to implantation for studies.
Click to Show/Hide
|
||||
| In Vivo Model | MDA-MB-231 xenograft model | ||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
References